Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Oramed Pharmaceuticals Inc.ORMP · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $230.9M[1]
Standard universeinsiderevenue above $1M and assets above $10M[1-2]
Warningslate filer, thin datanot computable: distress
Inputs computable5 of 14
Graded fromfilings received through Mar 26, 2026197 days before the rescan; every figure keyed to the SEC receipt date
Last close$4.212026-10-08; market equity $174.9M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$4NovDecJanFebMarAprMayJunJulAugSepOct$4.20
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Dec 21, 2012nonen/aQ1
Nov 21, 2014nonen/aQ2
Dec 21, 2021nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 26, 2026; the document on sec.gov.

—Description of Business— Intellectual Property and Patents.” commencing a new clinical trial for our oral insulin capsule, there are a variety of risks and uncertainties related to its development. top-line results from the phase 3 trial of our oral insulin capsule, which did not meet its primary or secondary endpoints, and indicated that we expect to discontinue oral insulin clinical activities for T2D. At present, following the results of the ORA-D-013-1 Phase 3 trial, we conducted a comprehensive analysis of the data and found that subpopulations of patients with pooled specific parameters responded well to oral insulin.

Warnings [top]

Late filer. found 1 NT 10-K/Q filings in the last eight quarters
Thin data. 5 of 14 grade factors are computable; minimum is 7

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 96.2
Gross profitability0.01%[1,3]32.2%95.13722025-12-31
Return on invested capitalnot computable9.3%
a prior annual debt, equity, and cash observation is required
Accruals ratio37.9%[1,4-6](6.6%)97.38112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 4
Solvency, sleeve percentile 25.5
Twelve-month failure probabilitynot computable0.07%
liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-primenot computable(0.31)
one or more required annual facts are missing
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio6.98x[7-8]2.96x25.58392025-12-31
Growth and financing, sleeve percentile 18.8
Revenue growth, three-year compoundnot computable10.0%
four consecutive annual observations are required
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
NOPAT must exceed $100,000
Asset growth, three years12.6%[1,6,9-10]2.1%28.37042025-12-31
Net share issuance, one year(1.0%)[11-12]2.5%9.36342026-03-26

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month104.0%8.0%89hotter than 89 of 100 peers
Distance from 52-week high(21.3%)(31.4%)64closer to its high than 64 of 100 peers
EBIT to enterprise value(6.4%)(1.5%)38pricier than 62 of 100 peers
Free cash flow yield(5.2%)(1.0%)40pricier than 60 of 100 peers
Book value to price1.820.2895pricier than 5 of 100 peers
Sales to price0.010.317pricier than 93 of 100 peers
Composite equity issuance, five years49.4%20.3%66more equity-funded than 66 of 100 peers
Relative strength against the sector, log excess return0.50(0.14)89ahead of 89 of 100 peers

Inputs: market equity $174.7M; EBIT -$15.1M; free cash flow -$9.2M; book equity $317.5M; sales $2.0M; debt $74.5M; cash $15.2M[13].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero41.2%✓ pass[4,6]
Operating cash flow above zero-$9.1M✗ fail[5]
Return on assets improved49.9 pts✓ pass[4,6,9,14]
Operating cash flow exceeds net income-$73.2M✗ fail[4-5]
Long-term leverage felln/a[1,6,9]
Current ratio improved(1,821.0 pts)✗ fail[7-8,15-16]
No new shares issued(1.0%)✓ pass[11-12]
Gross margin improvedn/a[2-3]
Asset turnover improvedn/a[2,6,9]
Cash, filings, liquidity
Cash and equivalents$15.2M[17]
Operating cash flow, four quarters-$5.2M[5,17-21]
Months of runway35.1
Late filings, two years1
NT 10-K or NT 10-Q
Days since last periodic filing60
10-Q received Aug 10, 2026
Median daily dollar volume$697,659
63 sessions
Days since newest grade input197

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$230.9M2025-12-312026-03-2610-Kfiling · viewer · series
2revenueus-gaap:Revenues$2.0M2025-12-312026-03-2610-Kfiling · viewer · series
3gross profitus-gaap:GrossProfit$13,0002025-12-312026-03-2610-Kfiling · viewer · series
4net incomeus-gaap:NetIncomeLoss$64.0M2025-12-312026-03-2610-Kfiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$9.1M2025-12-312026-03-2610-Kfiling · viewer · series
6assetsus-gaap:Assets$155.3M2024-12-312026-03-2610-Kfiling · viewer · series
7current assetsus-gaap:AssetsCurrent$133.3M2025-12-312026-03-2610-Kfiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$19.1M2025-12-312026-03-2610-Kfiling · viewer · series
9assetsus-gaap:Assets$220.6M2023-12-312025-03-2710-Kfiling · viewer · series
10assetsus-gaap:Assets$161.6M2022-12-312024-03-0610-Kfiling · viewer · series
11shares outstandingdei:EntityCommonStockSharesOutstanding40,446,1792026-03-262026-03-2610-Kfiling · viewer · series
12shares outstandingdei:EntityCommonStockSharesOutstanding40,850,4552025-03-272025-07-1610-K/Afiling · viewer · series
13shares outstandingdei:EntityCommonStockSharesOutstanding41,597,3542026-08-102026-08-1010-Qfiling · viewer · series
14net incomeus-gaap:NetIncomeLoss-$19.1M2024-12-312026-03-2610-Kfiling · viewer · series
15current assetsus-gaap:AssetsCurrent$143.2M2024-12-312026-03-2610-Kfiling · viewer · series
16current liabilitiesus-gaap:LiabilitiesCurrent$5.7M2024-12-312026-03-2610-Kfiling · viewer · series
17cashus-gaap:CashAndCashEquivalentsAtCarryingValue$15.2M2026-06-302026-08-1010-Qfiling · viewer · series
18operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.1M2026-06-302026-08-1010-Qfiling · viewer · series
19operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$2.9M2026-03-312026-05-1910-Qfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.7M2025-09-302025-11-1310-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$7.1M2025-06-302026-08-1010-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.